P1-894

Comprehensive analysis of seven Toll-like receptor genes including 15 singlenucleotide polymorphisms with autoimmune thyroid disease in Korean children.

Won Kyoung Cho¹, Jung-Pil Jang², Moon Bae Ahn¹, Shin Hee Kim¹, Kyoung Soon Cho¹, So Hyun Park¹, Min Ho Jung¹, Tai-Gyu Kim^{2,3} and Byung-Kyu Suh¹

¹ Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Seoul, Korea, Seoul, Korea, Seoul, Korea, Seoul, S Korea, ³ Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea

Background: The *Toll-like receptors* (*TLRs*) are germline-encoded receptors that play an essential role in initiating the immune response against pathogens. **Objective and hypotheses:** In this study, we assess the association of *TLR* polymorphism with autoimmune thyroid disease (AITD) in Korean children. Method: Seven *Toll-like receptor* genes (TLR-1, -2, -3, -4, -5, -6, -9) including 15 single-nucleotide polymorphisms were analyzed on 104 Korean children with AITD [Hashimoto's disease (HD) = 40, Graves' disease (GD) = 60

| | SNP Alleles | Normal | AITD |
|-----------------|-------------|--------------|--------------|
| | | n=183 (%) | n=104(%) |
| TLR1 (+742) | C | 163 (89.1%) | 92(88.5%) |
| rs4833095 | Т | 111 (60.7%) | 70(67.3%) |
| TLR2 (-16934) | Α | 144 (78.7%) | 84(80.8%) |
| rs4696480 | Т | 140 (76.5%) | 73(70.2%) |
| TLR2 (intron1) | Α | 142 (77.6%) | 83(79.8%) |
| rs1898830 | G | 140 (76.5%) | 75(72.1%) |
| TLR2 (3' UTR) | G | 129 (70.5%) | 82(78.8%) |
| rs7656411 | Т | 132 (72.1%) | 70(67.3%) |
| TLR3 (c.1243) | Α | 92 (50.3%) | 51(49.0%) |
| rs3775291 | G | 164 (89.6%) | 96(92.3%) |
| TLR3 (-7) | Α | 72 (39.3%) | 41(39.4%) |
| rs3775296 | C | 175 (95.6%) | 96(92.3%) |
| TLR4 (3'UTR) | C | 71 (38.8%) | 41(39.4%) |
| rs11536889 | G | 171 (93.4%) | 96(92.3%) |
| TLR4 (-1607) | C | 86 (47.0%) | 41(39.4%) |
| rs10759932 | Т | 166 (90.7%) | 98(94.2%) |
| TLR4 (Intron 1) | C | 156 (85.2%) | 90(86.5%) |
| rs1927911 | Т | 120 (65.6%) | 59(56.7%) |
| CC-TLR5 (+1174) | C | 183 (100.0%) | 104(100.0 %) |
| rs5744168 | Т | 4 (2.2%) | 3(2.9%) |
| CC-TLR6 (+745) | C | 183(100.0%) | 104(100.0%) |
| rs5743810 | G | 0(0.0%) | 0(0.0%) |
| TLR6 (c.*1833) | C | 139(76.0%) | 87(83.7%) |
| rs2381289 | Т | 142(77.6%) | 74(71.2%) |
| TLR9 (+2848) | Α | 117 (63.9%) | 69(66.3%) |
| rs352140 | G | 150 (82.0%) | 84(80.8%) |
| TLR9 (-1486) | C | 117 (63.9%) | 71(68.3%) |
| <u>rs187084</u> | Т | 148 (80.9%) | 84(80.8%) |
| TLR9 (3'UTR) | C | 117 (69.9%) | 70(67.3%) |
| rs352162 | Т | 147 (80.3%) | 84(80.8%) |
| | | | |

Table 3. Allele frequencies of TLR polymorphism in controls and AITD

(thyroid-associated ophthalmopathy (TAO) = 29, non-TAO = 31)] and 192

healthy individuals.



| ing I. Subjects classifications | Fig | 1. | Subj | jects | cla | assi | fica | ntio | ns |
|---------------------------------|-----|----|------|-------|-----|------|------|------|----|
|---------------------------------|-----|----|------|-------|-----|------|------|------|----|

 Table 1. Characteristics of 104 AITD patients

| Grouping | Characteristics | | | | | |
|----------------------------------|----------------------------------|-------------|--|--|--|--|
| Grouping | Sex (F/M) | 86/18 | | | | |
| | Age (years) at diagnosis | 11.3±3.2 | | | | |
| Control AITD | Age (years) at enrollment | 13.2±3.5 | | | | |
| | HD condition at diagnosis | | | | | |
| | Euthyroid state | 9 (20.5%) | | | | |
| Graves disease Hashimoto disease | Subclinical hypothyroid state | 6 (13.6%) | | | | |
| | Overt hypothyroid state | 23 (52.3%) | | | | |
| | Hyperthyroid state | 6 (13.6%) | | | | |
| IAO | HD patients on T4 replacement | 25 (56.8 %) | | | | |
| | Class of TAO | | | | | |
| 1. Subjects classifications | 0~1 No sign~ only sign | 75 | | | | |
| | 2 soft tissue involvement | 7 | | | | |
| | 3 Proptosis | 19 | | | | |
| | 4 Extraocular muscle involvement | 3 | | | | |
| | 5 Corneal involvement | 0 | | | | |
| Table 2. Primer sequences | for gight Mps of 7 TLRs | 0 | | | | |

| Gene | SNP | | Primer Sequence | |
|--------|------------|---|---|---------------------|
| | rs4833095 | F | GGATCCTAAT GAAAGAATTC CAAGTTGTTT CAATGTTGTT TAAGGTAATA | - ILK4 (IN |
| ILKI | (+742) | R | AAG ACC CTG AGG GCC TTC AAG AC | rs19279 |
| | rs4696480 | F | AACAGAAATTTATCCATTCATGGTT | - |
| | (-16934) | R | AGCAGTTTATTGTGAGAATGAGTTT | |
| τι σο | rs1898830 | F | CCCATGGGTC AAAAAATAAT CAG | |
| I LKZ | (intron1) | R | TAT TTT CTA GCA CAT TAA TTT CTA TTC TTA TAT | |
| | rs7656411 | F | TCT GGT CTT CCT CAG CCT CTA AC | |
| | (3' UTR) | R | CTA CCT TTA AAT TAC TGT GTA TCA AAC TAT TTT | |
| | rs3775291 | F | GCC GTG CTA AGT TGT TAT GCT GC>ATTCCTGGCC TGTGAGTTCT TGC | 100 ZZ GI |
| ті D 2 | (c.1243) | R | ACT TTG ACA AAT GAA ACA TTT GTA TCA CTT GCT | ^{90–} 🖬 Hi |
| ILKS | rs3775296 | F | CCGTTTGATGTATGACTTG | 80- |
| | (-7) | R | AAGTTGGCGGCTGGTAATCT | |
| | rs11536889 | F | GAG ACACAGATGG CTGGGA | |
| | (3'UTR) | R | TTC TGA GGA GGC TGG ATG AA | uen 50- |
| | rs10759932 | F | TATGATTAAA AGTGATTACC ACATTTTACA GACCAGAAAG TAATAATA <u>C</u> G | |
| ILK4 | (-1607) | R | GAC ACT TGC ATT GTT GCC ACA CG | |
| | rs1927911 | F | GCAGCAAATC ACCCTGGCAC ACA | 20- |
| | (Intron 1) | R | AGA TTT CCC CCT ATT TCT ACA TCA CTT TGC TCA | 10- |
| TLR5 | rs5744168 | F | ACACTC AAGGATTTGA AGGTTCTG | |
| | (+1174) | R | GAT ATC GGG TAT GCT TGG AAT AAA ATG AAT GGT | |
| | rs5743810 | F | GCATTTCCAAGTCGTTTCTATGT | - |
| | (+745) | R | GCAAAAACCCTTCACCTTGTT | Table 5. |
| ILKO | rs2381289 | F | ATA CCC TCT TCC CTT GCA ATG GC | |
| | (c.*1833) | R | TCC TGA ATC TTG GGC AGA TAC CAT AAA TTT TAG | |
| | rs352140 | F | AAGCTGGACCTCTACCACGA | |
| | (+2848) | R | TTGGCTGTGGATGTTGTT | ILR4 (In |
| τι do | rs187084 | F | ACTATGGAGCCTGCCTGCCATGATACC | rs19279′ |
| ILKY | (-1486) | R | ATCCAGCCTTCTTACAAACCTCCCACCC | |
| | rs352162 | F | AGATAGTGG TGCGCGGCTT CTCT | |
| | (3'UTR) | R | GAC TAT TCT GGC CAC AAT CAG G | |

Table 4. Significant association of *TLR 3, 4* genes with GD and HD patients

| | | Normal | GD | HD |
|-----------------|----|-------------|--------------------------------|------------------------|
| | | n=183 (%) | n= 60 (%) | n= 44 (%) |
| TLR3 (-7) | AA | 8 (4.4%) | 2 (3.3%) | 6 (13.6%) ^d |
| rs3775296 | AC | 64 (35.0%) | 20 (33.3%) | 13 (29.5%) |
| | CC | 111 (60.7%) | 38 (63.3%) | 25 (56.8%) |
| | Α | 72 (39.3%) | 22 (36.7%) | 19 (43.2%) |
| | С | 175 (95.6%) | 58 (96.7%) | 38 (86.4%) e |
| TLR4 (Intron 1) | CC | 63 (34.4%) | 32 (53.3%) ^a | 13 (29.5%) |
| rs1927911 | СТ | 93 (50.8%) | 20 (33.3%) ^b | 25 (56.8%) |
| | TT | 27 (14.8%) | 8 (13.3%) | 6 (13.6%) |
| | С | 156 (85.2%) | 52 (86.7%) | 38 (86.4%) |
| | Т | 120 (65.6%) | 28(46.7%) ^c | 31 (70.5%) |

TLR4 (rs1927911) Pc=0.032 *P*=0.01 Pc=NS Genotype / Allele

Fig 2. The frequencies of the TLR4 *rs1927911* CC genotype in HD was lower, whereas TLR4 rs 1927911 CT genotype in HD and *TLR4 rs1927911* T allele in HD showed higher frequencies than GD.

Association of TLR 4,9 genes with TAO and non-TAO patients

| | | Normal | Non-TAO | TAO |
|----------------------|----|-------------|-------------------------|------------|
| | | n=183 (%) | n= 31(%) | n= 29(%) |
| TLR4 (Intron 1) | CC | 63 (34.4%) | 17 (54.8%) ^a | 15 (51.7%) |
| rs1927911 | СТ | 93 (50.8%) | 11 (35.5%) | 9 (31.0%) |
| | TT | 27 (14.8%) | 3 (9.7%) | 5 (17.2%) |
| | С | 156 (85.2%) | 28 (90.3%) | 24 (82.8%) |
| | Т | 120 (65.6%) | 14(45.2%) b | 14 (48.3%) |
| <i>TLR-9</i> (-1486) | CC | 35 (19.1%) | 8 (27.6%) c | 2 (6.5%) |
| rs187084 | СТ | 82 (44.8%) | 12 (41.4%) | 19 (61.3%) |
| | TT | 66 (36.1%) | 9 (31.0%) | 10 (32.3%) |
| | С | 117 (63.9%) | 20 (69.0%) | 21 (67.7%) |
| | Т | 148 (80.9%) | 21 (72.4%) d | 29 (93.5%) |

Result-I:

•In total AITD, the frequencies of these alleles had no statistical difference with controls (Table 3).

•In HD, the frequencies of the TLR3 rs3775296 AA genotype (OR=3.45, P < 0.022) was higher, whereas the TLR3 rs3775296 C allele (OR=0.29, cP < 0.044) showed lower frequencies than in the healthy controls. In GD, the frequencies of the TLR4 rs1927911 CC genotype (OR=2.18, cP < 0.027) was higher, whereas the TLR4 rs1927911 CT genotype (OR=0.48, *P* < 0.018) and *TLR4 rs1927911* T allele (OR=0.46, c*P* < 0.018) showed lower frequencies than in the healthy controls(Table 4).

Result-II:

• In TAO, the frequencies of the TLR4 rs1927911 CC genotype was higher, whereas TLR4 rs1927911 T allele (OR=0.43, P < 0.029) showed lower frequencies than in the healthy controls. Between TAO and non-TAO, the frequencies of the TLR9 rs 187084 CC genotype in non-TAO (OR=5.52, P) < 0.028) was higher, whereas TLR9 rs 187084 T allele in non-TAO (OR=0.18, P < 0.028) was lower than TAO. However, the statistical significance was disappeared after correction.

Conclusion: Our results suggest that *TLR-3* and -4 gene polymorphisms may contribute to the pathogenesis of HD and GD.

